Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP10 | P09238 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 3/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970213 | 0.89 | MMP3 (0.41) | MMP3MMP10RAF1CYP4F2CYP4A11 | |
| SCHEMBL1972444 | 0.86 | AKR1C3 (0.50) | CYP4F2CYP4A11GRIA2NPC1RAB9A | |
| SCHEMBL1973863 | 0.84 | MEN1 (0.44) | CYP4F2CYP4A11F10F2SMN1; SMN2 | |
| SCHEMBL1973344 | 0.80 | TNKS (0.38) | HDAC8F10F2GRIA2NPC1 | |
| SCHEMBL2809179 | 0.78 | GRIA2 (0.57) | CYP4F2CYP4A11GRIA2 | |
| SCHEMBL1969371 | 0.77 | GRIA2 (0.39) | CYP4F2CYP4A11SMN1; SMN2TSHRGRIA2 | |
| SCHEMBL1971790 | 0.76 | GRIA2 (0.40) | GRIA2NR1H2MMP2MMP9ADAM17 | |
| SCHEMBL1972442 | 0.75 | AKR1C3 (0.50) | NPC1RAB9A | |
| SCHEMBL1973861 | 0.74 | MAPT (0.44) | CYP4F2CYP4A11F10F2SMN1; SMN2 | |
| SCHEMBL1970203 | 0.74 | GRIA2 (0.40) | SMN1; SMN2TSHRGRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236790-B2 | Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2012-08-07 | — | — | US | claimed |
| EP-2246339-B1 | Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors | SERVIER LAB (FR) | 2011-06-22 | — | — | EP | claimed |
| EP-2246339-A1 | Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors | Les Laboratoires Servier (FR) | 2010-11-03 | — | — | EP | claimed |
| WO-2010106249-A1 | BENZOTHIADIAZEPINE DERIVATIVES USED AS AMPA AND NMDA RECEPTOR MODULATORS | LES LABORATOIRES SERVIER (FR) | 2010-09-23 | — | — | WO | claimed |
| US-20100240635-A1 | Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-09-23 | — | — | US | claimed |
| US-8236790-B2 | Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2012-08-07 | — | — | US | disclosed |
| EP-2246339-B1 | Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors | SERVIER LAB (FR) | 2011-06-22 | — | — | EP | disclosed |
| EP-2246339-A1 | Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors | Les Laboratoires Servier (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20100240635-A1 | Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240635-A1 | Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | GRIN1, GRIN2B, GRIN3A | MMP3 4522/4885MMP10 4348/4885RAF1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.